1. Bray F, Ferlay J, Soerjomataram I, et al: Global Cancer Statistics 2018:
Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in
185 Countries. CA Cancer J Clin 2018;68:394-424.
2. Mayanagi S, Irino T, Kawakubo H, et al: Neoadjuvant Treatment Strategy for
Locally Advanced Thoracic Esophageal Cancer. Ann Gastroenterol Surg
2019;3:269-275.
3. Arnold M, Soerjomataram I, Ferlay, J, et al: Global incidence of esophageal
cancer by histological subtype in 2012. Gut 2015;64:381-387.
4. Mena S, Ortega A, Estrela JM: Oxidative Stress in Environmental-Induced
Carcinogenesis. Mutat Res 2009;674:36-44.
5. Bavarva JH, Tae H, Mclver L, et al: Nicotine and oxidative stress induced
exomic variations are concordant and overrepresented in cancer-associated
genes. Oncotarget 2014;5:4788-4798.
6. Yokoyama A, Kakiuchi N, Yoshizato T, et al: Age-Related Remodelling of
Oesophageal Epithelia by Mutated Cancer Drivers. Nature 2019;565:312-317.
7. Yamamoto M, Kensler TW, Motohashi H: The Keap1-Nrf2 System: A
Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol
Rev 2018;98:1169-1203.
8. Itoh K, Chiba T, Takahashi S, et al: An Nrf2/Small Maf Heterodimer Mediates
the Induction of Phase Ii Detoxifying Enzyme Genes through Antioxidant
Response Elements. Biochem Biophys Res Commun 1997;236:313-322.
9. Kobayashi A, Kang MI, Okawa H, et al: Oxidative Stress Sensor Keap1
Functions as an Adaptor for Cul3-Based E3 Ligase to Regulate Proteasomal
Degradation of Nrf2. Mol Cell Biol 2004;24:7130-7139.
10. Itoh K, Wakabayashi N, Katoh Y, et al: Keap1 Represses Nuclear Activation
of Antioxidant Responsive Elements by Nrf2 through Binding to the
Amino-Terminal Neh2 Domain. Genes Dev 1999;13:76-86.
11. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, et al: Direct Evidence That
Sulfhydryl Groups of Keap1 Are the Sensors Regulating Induction of Phase 2
Enzymes That Protect against Carcinogens and Oxidants. Proc Natl Acad Sci
U S A 2002;99:11908-11913.
12. Ramos-Gomez M, Kwak MK, Dolan PM, et al: Sensitivity to Carcinogenesis Is
Increased and Chemoprotective Efficacy of Enzyme Inducers Is Lost in Nrf2
Transcription Factor-Deficient Mice. Proc Natl Acad Sci U S A
2001;98:3410-3415.
13. Iida K, Itoh K, Kumagai Y, et al: Nrf2 Is Essential for the Chemopreventive
Efficacy of Oltipraz against Urinary Bladder Carcinogenesis. Cancer Res
2004;64:6424-6431.
14. Khor TO, Huang MT, Prawan A, et al: Increased Susceptibility of Nrf2
Knockout Mice to Colitis-Associated Colorectal Cancer. Cancer Prev Res
(Phila) 2008;1:187-191.
15. Satoh H, Moriguchi T, Takai J, et al: Nrf2 Prevents Initiation but Accelerates
Progression through the Kras Signaling Pathway During Lung
Carcinogenesis. Cancer Res 2013;73:4158-4168.
16. Wakabayashi N, Itoh K, Wakabayashi J, et al: Keap1-Null Mutation Leads to
Postnatal Lethality Due to Constitutive Nrf2 Activation. Nat Genet
2003;35:238-245.
17. Ohta T, Iijima K, Miyamoto M, et al: Loss of Keap1 Function Activates Nrf2
and Provides Advantages for Lung Cancer Cell Growth. Cancer Res
2008;68:1303-1309.
18. Shibata T, Ohta T, Tong KI, et al: Cancer Related Mutations in Nrf2 Impair
Its Recognition by Keap1-Cul3 E3 Ligase and Promote Malignancy. Proc Natl
Acad Sci U S A 2008;105:13568-13573.
19. Kim YR, Oh JE, Kim MS, et al: Oncogenic Nrf2 Mutations in Squamous Cell
Carcinomas of Oesophagus and Skin. J Pathol 2010;220:446-451.
20. Kitano Y, Baba Y, Nakagawa S, et al: Nrf2 Promotes Oesophageal Cancer Cell
Proliferation Via Metabolic Reprogramming and Detoxification of Reactive
Oxygen Species. J Pathol 2018;244:346-357.
21. Taguchi K, Yamamoto M: The Keap1-Nrf2 System in Cancer. Front Oncol
2017;7:85.
22. Ohkoshi A, Suzuki T, Ono M, et al: Roles of Keap1-Nrf2 System in Upper
Aerodigestive Tract Carcinogenesis. Cancer Prev Res (Phila) 2013;6:149-159.
23. Hiramoto K, Satoh H, Suzuki T, et al: Myeloid Lineage-Specific Deletion of
Antioxidant System Enhances Tumor Metastasis. Cancer Prev Res (Phila)
2014;7:835-844.
24. Maj T, Wang W, Crespo J, et al: Oxidative Stress Controls Regulatory T Cell
Apoptosis and Suppressor Activity and Pd-L1-Blockade Resistance in Tumor.
Nat Immunol 2017;18:1332-1341.
25. Fernandez-Antoran D, Piedrafita G, Murai K, et al: Outcompeting
P53-Mutant Cells in the Normal Esophagus by Redox Manipulation. Cell Stem Cell
2019;25:329-341.
26. Doupe DP, Alcolea MP, Roshan A, et al:A single progenitor population switches
behavior to maintain and repair esophageal epithelium. Science
2012;337:1091-1093.
27. Jiang M, Ku WY, Zhou Z, et al: Bmp-Driven Nrf2 Activation in Esophageal
Basal Cell Differentiation and Eosinophilic Esophagitis. J Clin Invest
2015;125:1557-1568.
28. Xue P, Hou Y, Chen Y, et al: Adipose Deficiency of Nrf2 in Ob/Ob Mice Results
in Severe Metabolic Syndrome. Diabetes 2013;62:845-854.
29. Blake DJ, Singh A, Kombairaju P, et al: Deletion of Keap1 in the Lung
Attenuates Acute Cigarette Smoke-Induced Oxidative Stress and
Inflammation. Am J Respir Cell Mol Biol 2010;42:524-536.
30. Okawa H, Motohashi H, Kobayashi A, et al: Hepatocyte-Specific Deletion of
the Keap1 Gene Activates Nrf2 and Confers Potent Resistance against Acute
Drug Toxicity. Biochem Biophys Res Commun 2006;339:79-88.
31. Watai Y, Kobayashi A, Nagase H, et al: Subcellular Localization and
Cytoplasmic Complex Status of Endogenous Keap1. Genes Cells
2007;12:1163-1178.
32. Katoh Y, Iida K, Kang MI, et al: Evolutionary Conserved N-Terminal Domain
of Nrf2 Is Essential for the Keap1-Mediated Degradation of the Protein by
Proteasome. Arch Biochem Biophys 2005;433:342-350.
33. Taguchi K, Maher JM, Suzuki T, et al: Genetic Analysis of Cytoprotective
Functions Supported by Graded Expression of Keap1. Mol Cell Biol
2010;30:3016-3026.
34. Yamamoto S, Inoue J, Kawano T, et al: The Impact of Mirna-Based Molecular
Diagnostics and Treatment of Nrf2-Stabilized Tumors. Mol Cancer Res
2014;12:58-68.
35. Hayes JD, McMahon M: The Double-Edged Sword of Nrf2: Subversion of
Redox Homeostasis During the Evolution of Cancer. Mol Cell 2006;21:732-734.
36. Sporn MB, Liby KT: Nrf2 and Cancer: The Good, the Bad and the Importance
of Context. Nat Rev Cancer 2012;12:564-571.
37. Hamada S, Taguchi K, Masamune A, et al: Nrf2 Promotes Mutant
K-Ras/P53-Driven Pancreatic Carcinogenesis. Carcinogenesis 2017;38:661-670.
38. Orru C, Szydlowska M, Taguchi K, et al: Genetic Inactivation of Nrf2 Prevents
Clonal Expansion of Initiated Cells in a Nutritional Model of Rat
Hepatocarcinogenesis. J Hepatol 2018;69:635-643.
39. Suzuki T, Seki S, Hiramoto K, et al: Hyperactivation of Nrf2 in Early Tubular
Development Induces Nephrogenic Diabetes Insipidus. Nat Commun
2017;8:14577.
40. Mitsuishi Y, Taguchi K, Kawatani Y, et al: Nrf2 Redirects Glucose and
Glutamine into Anabolic Pathways in Metabolic Reprogramming. Cancer Cell
2012;22:66-79.
41. Fu J, Xiong Z, Huang C, et al: Hyperactivity of the Transcription Factor Nrf2
Causes Metabolic Reprogramming in Mouse Esophagus. J Biol Chem
2019;294:327-340.
42. Scully R, Xie A: Double Strand Break Repair Functions of Histone H2ax.
Mutat Res 2013;750:5-14.
43. Wang J, Konishi T: Nuclear Factor (Erythroid-Derived 2)-Like 2 Antioxidative
Response Mitigates Cytoplasmic Radiation-Induced DNA Double-Strand
Breaks. Cancer Sci 2019;110:686-696.
44. Lan A, Li W, Liu Y, et al: Chemoprevention of Oxidative Stress-Associated Oral
Carcinogenesis by Sulforaphane Depends on Nrf2 and the Isothiocyanate
Moiety. Oncotarget 2016;7:53502-53514.
45. Sasaki H, Sato H, Kuriyama-Matsumura K, et al: Electrophile response
element-mediated induction of the cystine/glutamate exchange transporter
gene expression. J Bio Chem 2002;277:44765-44771.
46. Nunoshiba T, Demple B: Potent Intracellular Oxidative Stress Exerted by the
Carcinogen 4-Nitroquinoline-N-Oxide. Cancer Res 1993;53:3250-3252.
47. Tanuma J, Hirano M, Hirayama Y, et al: Genetic Predisposition to
4nqo-Induced Tongue Carcinogenesis in the Rat. Med Princ Pract 2005;14:297-305.
48. Kucinski I, Dinan M, Kolahgar G, et al: Chronic Activation of Jnk Jak/Stat
and Oxidative Stress Signalling Causes the Loser Cell Status. Nat Commun
2017;8:136.
49. Frede J, Greulich P, Nagy T, et al: A Single Dividing Cell Population with
Imbalanced Fate Drives Oesophageal Tumour Growth. Nat Cell Biol
2016;18:967-978.
50. Cuadrado A: Structural and functional characterization of Nrf2 degradation by
glycogen synthase kinase 3/beta-TrCP. Free Radic Biol Med 2015;88:147-157.
51. Sanchez-Vega F, Mina M, Armenia J, et al: Oncogenic Signaling Pathways in
The Cancer Genome Atlas. Cell 2018;173:321-337.
52. Cancer Genome Atlas Research N, et al: Integrated genomic characterization
of oesophageal carcinoma. Nature 2017;541:169-175.
53. Gen Y, Yasui K, Nishikawa T, et al: SOX2 promotes tumor growth of esophageal
squamous cell carcinoma through the AKT/mammalian target of rapamycin
complex1 signaling pathway. Cancer Sci 2013;104:810-816.